Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Have histologically confirmed colorectal cancer that is metastatic with measurable disease. * For the Phase II portion: Have recurred or progressed within 6 months of the last cycle of FOLFOX +/- bevacizumab first-line or adjuvant regimen for metastatic colorectal cancer. Note: Those who had initiated FOLFOX/CapOx but stopped oxaliplatin because of intolerable toxicity are also eligible. * At least 4 weeks have elapsed since the last chemotherapy, radiotherapy, immunotherapy, or biologic therapy prior to enrollment (except at least 6 weeks in the case of nitrosourea and mitomycin). * Have not received any other investigational agents within 4 weeks of study entry and have fully recovered from any adverse event due to prior therapy. * At least 4 weeks have elapsed since any major surgery. * Have ECOG performance status of 0, 1, or 2. * Have adequate bone marrow and organ function Exclusion Criteria: * Have an active, uncontrolled infection. * Have known HIV positive status. * Have known or suspected cerebral metastasis. * Have had a myocardial infarction (MI) or cerebrovascular accident (CVA) within the last 6 months; or meet the criteria for AHA class III or IV congestive heart failure (CHF). * Have a medical condition requiring chronic use of high-dose corticosteroids or other chronic immunosuppressive therapy (e.g. methotrexate, azathioprine). * Have a history of greater than or equal to Grade 2 allergic reaction or hypersensitivity following exposure to humanized or human monoclonal antibodies (but not chimeric antibodies). * Pregnant or breastfeeding women and male or female patients who do not agree to use effective contraceptive method(s) during the study.